-
Autolus Therapeutics NasdaqGS:AUTL Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Location: The Mediaworks, White City, London, W12 7FP, United Kingdom | Website: https://www.autolus.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
36.54M
Cash
588M
Avg Qtr Burn
-51.57M
Short % of Float
8.29%
Insider Ownership
18.09%
Institutional Own.
85.87%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AUCATZYL® (obecabtagene autoleucel) (obe-cel) Details Acute lymphoblastic leukemia, Cancer, Blood cancer | Approved Quarterly sales | |
AUTO4 Details Peripheral T cell cancer | Phase 1/2 Update | |
AUTO1/22 (CD19 & CD22) Details Cancer, Leukemia, Pediatric Acute lymphoblastic leukemia | Phase 1 Data readout | |
AUTO6NG Details Solid tumor/s, Neuroblastoma | Phase 1 Data readout | |
obe-cel (AUTO1) (CD19) Details Lymphoma, Leukemia, Cancer, Central nervous system illness, primary central nervous system lymphomas | Phase 1 Data readout | |
AUTO8 (BMCA & CD19) Details Multiple myeloma | Phase 1 Data readout | |
obe-cel (AUTO1) (CD19) Details Systemic lupus erythematosus | Phase 1 Data readout | |
obe-cel (AUTO1) (CD19) Details Lymphoma, Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Cancer, Leukemia | Phase 1 Update | |
AUTO5 Details T-cell lymphoma | Phase 1 Initiation | |
obe-cel Details Multiple Sclerosis (MS) | Phase 1 Initiation | |
AUTO3 (CD19, CD22) Details Lymphoma, Diffuse large B cell lymphoma, Cancer | Failed Discontinued |